Pancreatic Neuroendocrine Tumor
47
11
16
17
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.4%
3 terminated out of 47 trials
85.0%
-1.5% vs benchmark
0%
0 trials in Phase 3/4
35%
6 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (47)
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
AI-Powered Precision Decision-Making for Pancreatic Diseases
Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction